XML 133 R76.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Other (Income)/Deductions - Net - Footnotes - Additional Information (Details) - USD ($) $ in Millions |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Apr. 08, 2016 | Oct. 31, 2018 | Sep. 30, 2018 | Apr. 30, 2018 | Jul. 01, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Gain associated with Bain Capital transaction | [2] |  |  |  |  |  | $ 586 | [1] | $ 224 | $ 18
Change in fair value of fair value contingent consideration liabilities |  |  |  |  |  |  | 207 |  |  |
Income from resolution of contract disagreement |  |  |  |  |  |  |  |  | 62 | 116
Payments for merger termination costs |  | $ 150 |  |  |  |  |  |  |  | $ 150
Allogene [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Gain from contribution agreement |  |  |  |  |  | $ 50 | 50 |  |  |
Ownership percentage |  |  | 18.00% |  | 25.00% |  |  |  |  |
ViiV Healthcare Limited [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Dividend income |  |  |  |  |  |  | 253 |  |  |
Innovative Health Segment [Member] | ViiV Healthcare Limited [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Dividend income |  |  |  |  |  |  |  |  | 266 |
Operating Segments [Member] | Innovative Health Segment [Member] | ViiV Healthcare Limited [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Dividend income |  |  |  |  |  |  | 253 |  | $ 266 |
Segment Reconciling Items [Member] | Allogene [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Gain from contribution agreement |  |  |  |  |  |  | 50 |  |  |
Bain Capital [Member] | Cerevel [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Gain associated with Bain Capital transaction |  |  |  | $ 343 |  |  | 343 |  |  |
Bain Capital [Member] | Segment Reconciling Items [Member] | Cerevel [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Gain associated with Bain Capital transaction |  |  |  |  |  |  | 343 |  |  |
European Union [Member] | Mylotarg [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Gain from cash settlement of liability |  |  |  |  |  | $ 17 | 17 |  |  |
2017-2019 Initiatives and Organizing for Growth Initiative [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Legal, tax and advisory service expense |  |  |  |  |  |  | 59 |  |  |
2017-2019 Initiatives and Organizing for Growth Initiative [Member] | Segment Reconciling Items [Member] |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Legal, tax and advisory service expense |  |  |  |  |  |  | $ 59 |  |  |
[1] | The net gains on investments in equity securities are reported in Other (income)/deductions––net and, for 2018, include unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. For additional information, see Note 4.
[2] | The net gains on investments in equity securities in 2018, include unrealized net gains on equity securities of $477 million, reflecting the adoption of a new accounting standard in the first quarter of 2018. Net gains in 2018 were primarily driven by unrealized gains of $466 million related to our investment in Allogene. Prior to the adoption of a new accounting standard in the first quarter of 2018, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B, Note 2B and Note 7B.

X
- Definition Gain (Loss) From Contribution Agreement + References No definition available. + Details
Name: | pfe_GainLossFromContributionAgreement
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investment, Ownership Percentage + References No definition available. + Details
Name: | pfe_InvestmentOwnershipPercentage
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Legal, Tax And Advisory Service Expense + References No definition available. + Details
Name: | pfe_LegalTaxAndAdvisoryServiceExpense
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Other Nonoperating Income, Miscellaneous + References No definition available. + Details
Name: | pfe_OtherNonoperatingIncomeMiscellaneous
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for Merger Termination Costs + References No definition available. + Details
Name: | pfe_PaymentsforMergerTerminationCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and Development Arrangement, Gain From Liability Extinguishment + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of dividend income on nonoperating securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(a)) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_InvestmentIncomeDividend
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_BainCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MylotargMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |